The Transgenic OT-II T Cell Receptor mouse was developed by Dr. Francis Carbone of Monash Medical School and Dr. William R. Heath of the Walter and Eliza Hall Institute. The model was created by microinjecting the rearranged Vα2 and Vβ5 T cell receptor into B6 x B6.C-H2bm1 blastocysts. Founders were subsequently bred to B6 mice. The line was later transferred to the NIAID repository at Taconic from Eric Butz of the Immunex Corporation. The transgenic mice were crossed twice to a homozygous Rag1 knockout mouse on a B6 background (Mombaerts P, Cell 1992;68:869-877, generated through gene targeting in 129S7-derived ES cells) and Rag1-/- offspring were selected. These mice were then intracrossed to produce the line homozygous for the TCR transgene. TCR positive mice homozygous for the transgene were identified by test mating the mice to wild type partners and selecting animals that only gave rise to transgene positive offspring.
Barnden MJ, Allison J, Heath WR ,Carbone FR; Defective TCR expression in transgenic mice constructed using cDNA-based α- and β- chain genes under the control of heterologous regulatory elements. Immunol Cell Biol February 1998 76(1) pp.34-40.
Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR.; Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001 166 pp.6099-6103.
Mombaerts P, Iacomini J, Johnson RS, Herrup I, Tonegawa S, Papaioannou VE. 1992. RAG-1 deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.